Heppenheim, Germany

Roland Kellner

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roland Kellner. Retrieved from https://idiyas.com/inventor/roland-kellner-3wm6tt27

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:

goldMedal1 out of 834,513 
Other
 patents

Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Roland Kellner - Innovator in Antibiotic Development

Introduction

Roland Kellner is a notable inventor based in Heppenheim, Germany. He has made significant contributions to the field of antibiotic research, particularly with his work on polycyclic peptide antibiotics. His innovative approach has led to the development of new therapeutic agents that can combat bacterial infections.

Latest Patents

Kellner holds a patent for a polycyclic peptide antibiotic known as gallidermin. This antibiotic is produced through the fermentation of a newly identified microorganism, Staphylococcus gallinarum (DSM 4616). The patent highlights the unique properties of gallidermin and its potential applications in medicine.

Career Highlights

Throughout his career, Kellner has focused on advancing antibiotic research. His work has been instrumental in exploring new avenues for treating bacterial infections, which is a critical area of concern in modern medicine. His dedication to innovation has positioned him as a key figure in the field.

Collaborations

Kellner has collaborated with notable colleagues, including Friedrich Gotz and Thomas Horner. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in antibiotic development.

Conclusion

Roland Kellner's contributions to antibiotic research, particularly through his patent for gallidermin, underscore his role as an innovator in the field. His work continues to influence the development of new therapeutic agents that can address pressing health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…